TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29362444
Drug: Active minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active minocycline + placebo aspirin (M + P)
Study: 29362444
Drug: Placebo-minocycline +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-minocycline + active aspirin (A + P)
Study: 29362444
Drug: Placebo-minocycline +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-minocycline + placebo aspirin (P + P)
Study: 24033822
Drug: 2% niacinamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% niacinamide + 2% tranexamic acid (TXA) cream (test formulation; n = 21)
Study: 24033822
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control cream (n = 21)
Study: 19026251
Drug: Triple-bead mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-bead mixed amphetamine salts (MAS) (12.5 mg to 75 mg)
Study: 12663706
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant therapy or a single cycle of perioperative chemotherapy for node-negative disease (1,275 women)
Study: 12663706
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy of at least 3 months' duration and/or tamoxifen for node-positive disease (4,077 women)
Study: 10972581
Drug: Diet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet therapy for 3 months
Study: 9370178
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with anti-thymocyte globulin (ATG) 20 mg/kg/d for 7 to 14 days
Study: 9370178
Drug: CsA 8
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA 8 mg/kg/d started immediately before surgery with diltiazem 60 mg sustained release twice daily
Study: 9370178
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with anti-thymocyte globulin (ATG)
Study: 1583321
Drug: Single 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 5 x 10(8) cfu dose
Study: 1583321
Drug: Single 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 5 x 10(9) cfu dose
Study: 1583321
Drug: Second 5
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second 5 x 10(9) cfu dose one week later
Study: 1583321
Drug: Increasing vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing vaccine dose to 5 x 10(9) cfu
Study: 3896281
Drug: Nicardipine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (average daily dose 84 mg, range 40-160 mg)
Study: 22352509
Drug: Vocoders that
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vocoders that simulated aspects of cochlear implant processing
Study: 15778880
Drug: Donepezil (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (up to 10 mg/day for 8 weeks)
Study: 11836593
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of anticancer drug alone (method A)
Study: 11836593
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation plus oral chemotherapy (doxifluridine, 5'‐DFUR) (method B)
Study: 8750168
Drug: Propranolol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (160 mg/d for 1 week)
Study: 8750168
Drug: Aspirin stimulation
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin stimulation test
Study: 1897264
Drug: Western therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western therapy (dihydrochlorothiazide and atenolol)
Study: 1897264
Drug: Chinese traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese traditional therapy (mixtures of nine herbs and other ingredients)
Study: 31471753
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT angiography using ASiR-V
Study: 28113240
Drug: Closed-loop insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop insulin delivery over 12 weeks
Study: 24982375
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg doxorubicin loaded Super Absorbent Polymer microspheres
Study: 24982375
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg doxorubicin loaded Super Absorbent Polymer microspheres
Study: 24982375
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg doxorubicin loaded Super Absorbent Polymer microspheres
Study: 24982375
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg (bland embolic)
Study: 24982375
Drug: Bland embolic
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bland embolic vs drug-loaded groups
Study: 3392652
Drug: Caffeine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (600 mg)
Study: 9219047
Drug: Dextroamphetamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (20 mg)
Study: 17845167
Drug: 0.5% malathion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% malathion gel (30 minutes application)
Study: 17845167
Drug: Ovide Lotion
Normalized name: malathion Topical Lotion [Ovide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovide Lotion (0.5% malathion)
Study: 15447735
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg once a day for four days)
Study: 11678783
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (200 ml, double strength, three times a day for 2 days)
Study: 9834260
Drug: SR27417A (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR27417A (10 mg/day)
Study: 1103617
Drug: Buffered infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered infusion fluid or 24-hour change of administration set
Study: 1103617
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy with inline filters
Study: 26203826
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg tabalumab every 4 weeks (120/Q4W)
Study: 26203826
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg tabalumab every 2 weeks (90/Q2W)
Study: 16481387
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (daily doses of </=500 microg)
Study: 28796990
Drug: Granulocyte/monocyte apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte/monocyte apheresis (GMA) with the Adacolumn as remission induction therapy
Study: 25924545
Drug: Single Flap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Flap Approach (SFA) with rhPDGF‐BB (0.3 mg/ml) + β‐TCP
Study: 25924545
Drug: Double Flap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double Flap Approach (DFA) with rhPDGF‐BB (0.3 mg/ml) + β‐TCP
Study: 23470303
Drug: α-lipoic acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-lipoic acid supplementation (1000 mg daily for 14 days)
Study: 14622079
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy (PST) with significant other
Study: 10606851
Drug: Identical cream
Normalized name: MENTHOL 20 g in 100 mL TOPICAL EMULSION [DentiCalm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical cream with 5% salicylic acid, omitting sodium nitrite
Study: 2228838
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g iv
Study: 121165
Drug: Prophylactic granulocyte
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic granulocyte transfusions (daily at least 1.1010 granulocytes per square meter from the last day of treatment until the 12th day of aplasia)
Study: 28234436
Drug: Immediate discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate discontinuation of prior antipsychotics at baseline
Study: 28234436
Drug: Gradual discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual discontinuation of prior antipsychotics by reducing 25% each week
Study: 15821379
Drug: Butorphanol 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 0.04 mg/kg
Study: 9778225
Drug: Intravenous pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pulse administration of cyclophosphamide (0.75 gm/m2)
Study: 9778225
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral cyclophosphamide treatment (2 mg/kg body weight)
Study: 27484113
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity focused ultrasound (HIFU) treatment
Study: 27484113
Drug: Whole lesion
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole lesion ablation (comparison for treatment time)
Study: 20201089
Drug: Ferumoxytol (Feraheme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxytol (Feraheme injection) administered as two 510 mg IV injections, separated by 3-8 days
Study: 20201089
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (Ferro-Sequels) administered at a dose of 100 mg twice daily for 21 days
Study: 11227291
Drug: Certoparin (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certoparin (18 mg)
Study: 11227291
Drug: Dalteparin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (30 mg)
Study: 11227291
Drug: Enoxaparin (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (24 mg)
Study: 12796608
Drug: Tamoxifen 40
Normalized name: tamoxifen 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 40 mg daily
Study: 8390529
Drug: Enalapril pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril pretreatment (5 mg/day for 5 days)
Study: 8390529
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Enalapril and Noradrenaline
Study: 2894971
Drug: Felodipine (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (initial dose 2.5mg bid, titrated to 5, 10, 20mg bid)
Study: 2894971
Drug: Prazosin (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (initial dose 0.5mg bid, titrated to 1, 2, 4mg bid)
Study: 30352054
Drug: GSK3532795 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3532795 (60 mg, 120 mg, or 180 mg QD) + TDF/FTC (300/200 mg QD)
Study: 30352054
Drug: Efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz (EFV) (600 mg QD) + TDF/FTC (300/200 mg QD)
Study: 22963595
Drug: Computerized Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized Cognitive Behavioral Therapy (cCBT)
Study: 12608543
Drug: Oxybutynin transdermal
Normalized name: oxyBUTYnin Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin transdermal system (TDS) applied to abdomen
Study: 12608543
Drug: Oxybutynin transdermal
Normalized name: oxyBUTYnin Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin transdermal system (TDS) applied to buttock and hip
Study: 12608543
Drug: Oxybutynin transdermal
Normalized name: oxyBUTYnin Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin transdermal system (TDS)
Study: 12608543
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro Oxybutynin skin absorption
Study: 8619355
Drug: Iobitridol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iobitridol (300 mg I/ml)
Study: 6206687
Drug: Iohexol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol (300 mg I/ml)
Study: 1768163
Drug: Pamidronate 30
Normalized name: pamidronate 30 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 30 mg weekly for six weeks (Group 1)
Study: 1768163
Drug: Pamidronate 60
Normalized name: pamidronate 60 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 60 mg weekly for three weeks (Group 1A)
Study: 1768163
Drug: Pamidronate 45
Normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate 45 mg every three months for one year (Group 2)
Study: 6755247
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (Heptavax‐B)
Study: 23567441
Drug: venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: venlafaxine XR (up to 300 mg/day) for 12 weeks
Study: 19299803
Drug: Placebo perineural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo perineural femoral infusion
Study: 17519647
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 mg)
Study: 15292480
Drug: C&E (caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: C&E (caffeine 70 mg/dose and ephedra 24 mg/dose)
Study: 7901473
Drug: Corticosteroids (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (40 mg prednisolone daily, tapered and stopped after 12 weeks)
Study: 3629220
Drug: Intramuscular gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular gold therapy
Study: 3629220
Drug: Oral penicillamine
Normalized name: Penicillamine
DrugBank: Penicillamine (DB00859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral penicillamine therapy
Study: 27487463
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of ofloxacin both one day and one hour before IVI (eight doses)
Study: 12594647
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of secondary prophylaxis for PCP
Study: 9846777
Drug: Gabapentin (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (titrated from 900 to 3600 mg/d or maximum tolerated dosage)
Study: 2571354
Drug: Prescription information
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription information leaflets (PILs) for penicillins, diuretics, and benzodiazepines
Study: 25532865
Drug: delta-9-THC (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: delta-9-THC (10 mg)
Study: 18590259
Drug: DP-a (hydrofluoric
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP-a (hydrofluoric acid treatment)
Study: 18590259
Drug: DP-s (sandblasting
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP-s (sandblasting treatment)
Study: 18590259
Drug: IC-s (sandblasting
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC-s (sandblasting treatment)
Study: 18590259
Drug: IC-a (hydrofluoric
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC-a (hydrofluoric acid treatment)
Study: 15294013
Drug: FP/salmeterol 100/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP/salmeterol 100/50 microg twice daily via Diskus inhaler
Study: 15294013
Drug: FP +
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP + montelukast 100 microg twice daily via Diskus inhaler plus oral montelukast 10mg once daily
Study: 7523181
Drug: rhG‐CSF administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhG‐CSF administration
Study: 7523181
Drug: H 7
Normalized name: Isolyte S PH 7.4
DrugBank: Sodium phosphate, dibasic, unspecified form (DB14504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H 7 (10 mumol/l) or H 8 (20 mumol/l) co-incubation
Study: 1111913
Drug: BCNU 150
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BCNU 150 mg/m2 and vincristine 2 mg/m2 given every 30 days
Study: 1111913
Drug: DTIC 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC 300 mg/m2/day x 6 given every 30 days
Study: 1111913
Drug: DTIC 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC 100 mg/m2/8 hours x 18 given every 30 days
Study: 28464042
Drug: Etoricoxib 90
Normalized name: etoricoxib 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 90 mg qd for six months (long-term)
Study: 28464042
Drug: Etoricoxib 90
Normalized name: etoricoxib 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 90 mg qd for six months (short-course)
Study: 28464042
Drug: Etoricoxib 90
Normalized name: etoricoxib 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 90 mg qd for six months
Study: 26639505
Drug: D-Worm (herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-Worm (herbal medicine)
Study: 26639505
Drug: Mebandazole (allopathic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebandazole (allopathic drug)
Study: 14530608
Drug: Low-dose ACTH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ACTH test (LDAT) 0.5 microg/m2
Study: 14530608
Drug: Standard-dose ACTH
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose ACTH test (SDAT) 250 microg/m2
Study: 14530608
Drug: Low-dose ACTH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ACTH test (LDAT)
Study: 14530608
Drug: Standard-dose ACTH
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose ACTH test (SDAT)
Study: 6819275
Drug: Neutron therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutron therapy (20 daily fractions over four weeks)
Study: 6819275
Drug: Photon therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photon therapy (20 daily fractions over four weeks)
Study: 21525191
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus vitamin D (CaD) supplements: 500 mg calcium carbonate plus 200 IU vitamin D(3) twice daily (1000 mg and 400 IU daily, respectively) for an average of 7.0 years.
Study: 8814649
Drug: Ethanol (0.55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.55 g/kg)
Study: 8814649
Drug: Ethanol (0.55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.55 g/kg) with deviant tones
Study: 1325036
Drug: Azithromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1 g once orally)
Study: 1325036
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg orally twice daily for seven days)
Study: 30266729
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose RS2 (48 g daily for 2 weeks)
Study: 30266729
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose RS2 (3 g/2,500 kcal daily for 2 weeks)
Study: 25178924
Drug: O₃ (0.300
Approvals — FDA: no, EMA: no, PMDA: no
Description: O₃ (0.300 ppm) + DE (300 μg/m³)
Study: 25178924
Drug: DE (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: DE (300 μg/m³)
Study: 21942262
Drug: bupropion (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupropion (300 mg/day)
Study: 19623601
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg/day for 6 weeks, then 10 mg/day thereafter
Study: 17305413
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium 12.5mg tablets
Study: 17305413
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium 25mg (2 tablets)
Study: 17305413
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium and ibuprofen
Study: 12066736
Drug: Topical 4%
Normalized name: menthol topical 4% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 4% amethocaine gel (Ametop)
Study: 10223780
Drug: Ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5 mg to 20 mg for 8 weeks)
Study: 7910470
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg suriclone
Study: 7910470
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg suriclone
Study: 19178124
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDT) with peripheral blood stem cell transplant (PBSCT) support
Study: 19178124
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy regimen (CHOP)
Study: 9413023
Drug: GHB (gammahydroxy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB (gammahydroxy butyric acid) at a dose of 25 mg/kg body weight
Study: 3464742
Drug: Stomatognathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stomatognathic treatment
Study: 24948347
Drug: Delayed-release cysteamine
Normalized name: cysteamine Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release cysteamine bitartrate (DR-CYS)
Study: 20423222
Drug: AS03-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted vaccine (11.86 mg or 5.93 mg of tocopherol)
Study: 20423222
Drug: Both AS03-adjuvanted
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both AS03-adjuvanted and nonadjuvanted vaccines
Study: 11784224
Drug: High daily
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High daily alcohol intake
Study: 11784224
Drug: Uric acid
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uric acid (HR per 1 mmol/L increase)
Study: 10362188
Drug: Low-dose argatroban
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose argatroban